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Abstract
Rationale: In primary ciliary dyskinesia, factors leading to disease
heterogeneity are poorly understood.
Objectives: To describe early lung disease progression in primary
ciliary dyskinesia and identify associations between ultrastructural
defects and genotypes with clinical phenotype.
Methods: This was a prospective, longitudinal (5 yr), multicenter,
observational study. Inclusion criteria were less than 19 years at
enrollment and greater than or equal to two annual study visits.
Linear mixed effects models including random slope and random
intercept were used to evaluate longitudinal associations between the
ciliary defect group (or genotype group) and clinical features (percent
predicted FEV1 and weight and height z-scores).
Measurements and Main Results: A total of 137 participants
completed 732 visits. The group with absent inner dynein arm,
central apparatus defects, and microtubular disorganization
(IDA/CA/MTD) (n = 41) were significantly younger at diagnosis and
in mixed effects models had significantly lower percent predicted
FEV1 and weight and height z-scores than the isolated outer dynein
arm defect (n = 55) group. Participants with CCDC39 or CCDC40
mutations (n = 34) had lower percent predicted FEV1 and weight and
height z-scores than those with DNAH5mutations (n = 36). For the
entire cohort, percent predicted FEV1 decline was heterogeneous
with a mean (SE) decline of 0.57 (0.25) percent predicted/yr. Rate of
decline was different from zero only in the IDA/MTD/CA group
(mean [SE],21.11 [0.48] percent predicted/yr; P = 0.02).
Conclusions: Participants with IDA/MTD/CA defects, which
included individuals withCCDC39 orCCDC40mutations, hadworse
lung function and growth indices compared with those with outer
dynein arm defects and DNAH5mutations, respectively. The only
group with a significant lung function decline over time were
participants with IDA/MTD/CA defects.
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In primary ciliary dyskinesia (PCD),
abnormal function of motor cilia lining the
respiratory epithelium leads to impaired
mucociliary clearance, resulting in recurrent
or chronic bacterial infections of the
airways, paranasal sinuses, and middle
ear. Lower and upper respiratory tract
manifestations, such as recurrent or
persistent bronchitis, sinusitis, and otitis
media, typically begin during infancy (1–3).
Chronic atelectasis, bronchiectasis, and
airflow limitation are frequently apparent
by early childhood (4–6).
Pathogenic variants in PCD-causing
genes lead to specific ultrastructural defects,
and genotype-phenotype relationships are
emerging in PCD. Specifically, variability in
the severity and progression of lung disease
in PCD may be related to the underlying
ultrastructural or genetic defect (5–7). In a
cross-sectional study of children and
adolescents with confirmed PCD (5),
growth parameters and spirometry indices
were worse in participants who had absent
inner dynein arm (IDA), central apparatus
abnormalities (CA), and microtubular
disorganization (MTD) compared with
participants with isolated outer dynein
arm (ODA) or combined ODA/IDA
defects. Most (75%) participants with
IDA/CA/MTD ultrastructural defects had
biallelic pathogenic variants in CCDC39
or CCDC40. However, there are little
longitudinal data (6, 7) evaluating the
impact of specific ultrastructural or genetic
defects on progression of respiratory
disease in children and adolescents with
PCD.
Streptococcus pneumoniae,
Staphylococcus aureus, and nontypable
Haemophilus influenzae are common
bacterial isolates in PCD sputum (8–10).
Pseudomonas aeruginosa is reported in
sputum samples from children, but is more
prevalent in adults with PCD (5, 9, 10).
However, the evolution of PCD pathogen
prevalence with age and its relationship
to ultrastructural or genetic defects has
not been systematically evaluated in the
pediatric population.
The primary objectives of this study are
to describe the age-related progression of
early lung disease in PCD and identify
associations between genotypes and
ultrastructural defects with clinical
phenotypes in the pediatric population. We
hypothesize that lung disease progresses
over time and that specific ciliary
ultrastructural abnormalities and their
associated genetic defects will segregate
into clinical phenotypes with different
pathogen prevalence, severities, and
trajectories of airway obstruction and
growth metrics. In this era of precision
medicine, elucidating the longitudinal
course of this rare genetic lung disease is
imperative to further the understanding
of its pathogenesis and progression. Some
of the results of this study have been




This was a prospective, longitudinal,
multicenter, observational study.
Study Sites and Participants
As previously described (5), study
participants were enrolled at seven sites
participating in the Genetic Disorders
of Mucociliary Clearance Consortium
between 2006 and 2011. At enrollment,
participants were less than 19 years of age
with a diagnosis of confirmed, probable,
or possible PCD. Study visits occurred
annually for up to 5 years (six study visits).
The cohort for the current analysis was
limited to those with confirmed PCD
(abnormal ciliary ultrastructure by
transmission electron microscopy and/or
genetic mutations consistent with PCD along
with compatible clinical features) who had
two or more study visits. Institutional review
board approval was obtained at each site.
Informed consent and assent were acquired
from parents and participants, when
appropriate. An observational safety
monitoring board reviewed and approved
all clinical protocols.
Study Procedures
Study procedures have been described
previously (5). Briefly, standardized
procedures were used for diagnostic testing
(evaluation of ciliary ultrastructure from
transmission electron micrographs [EM]
and mutation screening for .30 PCD-
causing genes) (5) and for annual
assessment of clinical features including
medical history, physical examination,
spirometry (preschool spirometry in those
3–5 yr of age and standard spirometry in
those .5 yr of age), and a respiratory
culture from a deep oropharyngeal swab
or expectorated sputum. All EMs were
reviewed in a blinded fashion by three
expert reviewers at the University of North
Carolina at Chapel Hill (5). To confirm an
isolated IDA defect, two to three nasal
epithelial biopsies must be conducted at
different time points. Between 25% and
30% of IDA defects on the first biopsy are
normal on repeat biopsy (12, 13). To date,
no genetic defect has been associated with
an IDA defect alone. These annual
assessments were conducted when the
participants were healthy or free from
acute illness for 4 weeks. All spirometry
measurements were over-read for participants
less than 7 years of age.
Statistical Analysis
Descriptive statistics are presented for
the entire cohort and for five ciliary
ultrastructure defect groups: 1) isolated
At a Glance Commentary
Scientific Knowledge on the
Subject: In children with primary
ciliary dyskinesia, abnormal
ultrastructure and/or function of
respiratory cilia leads to upper and
lower respiratory tract disease that
typically begins during infancy.
Respiratory manifestations are
heterogeneous, and ultrastructural and
genotype–phenotype relationships are
emerging in primary ciliary dyskinesia.
The factors leading to longitudinal
changes in lung disease are poorly
understood in this population.
What This Study Adds to the
Field: This multicenter, prospective
study detected different clinical
phenotypes based on ciliary
ultrastructural defect group and the
corresponding genotype. Children who
had absence of inner dynein arm with
central apparatus defects and
microtubular disorganization had
poorer lung function at all ages
compared with those with isolated
outer dynein arm defects. Furthermore,
this was the only group that had a
significant decline in lung function
over time. Those with CCDC39 or
CCDC40 genetic mutations also had
significantly diminished lung function
and growth parameters compared with
those with genetic mutations in
DNAH5.
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ODA defects, 2) ODA/IDA defects, 3)
absence of IDA in conjunction with CA
defects and MTD, 4) normal ultrastructure
on EM with genetic mutations consistent
with PCD, and 5) other defects (oligocilia
and isolated CA defects).
Baseline characteristics were compared
between the ODA defect group (the most
prevalent group) and the other ciliary
ultrastructural defect groups using general
linear models for continuous characteristics
and logistic regression for dichotomous
outcomes. To evaluate the association
between ciliary ultrastructure defect group
and clinical features (percent predicted
FEV1 [14] and weight-for-age z-scores and
height-for-age z-scores), we used linear
mixed effects models for all repeated
measurements from each participant,
including random slope (within subject
change) and random intercept (subject
specific difference) (15). We first examined
a model including ultrastructure defect
group, age in years, and the interaction
between them as fixed effects. When the
interaction term was not statistically
significant, it was removed from the model,
and we estimated the overall association
between the clinical feature and defect
group, assuming it was not different by age.
We also performed a sensitivity analysis
eliminating all spirometric measurements
for participants 3–5 years of age due to
potential differences between preschool
spirometry and standard spirometry.
Generalized estimating equations with a
logit link were used to compare respiratory
pathogen prevalence between defect groups.
Two-sided P values less than 0.05 were
considered statistically significant. Analyses
were performed using SAS version 9.4.
Results
Participant Characteristics
Of the 171 study participants, 137 had a
definite diagnosis of PCD and participated
in at least two study visits; these individuals
comprised the cohort for the current
analysis (Figure 1). These participants
completed 732 study visits, with a median
of six visits per participant (range, 2–6); 91
participants completed all six annual study
visits. Median (range) follow-up was 6
(1–6) years. The ciliary ultrastructural
defects and genetic mutations (two
pathogenic or likely pathogenic variants
in a known PCD-associated gene; or, for
X-linked cases, one pathogenic variant in
the X chromosome in males) are shown
in Table 1: a total of 55 had isolated ODA
defects, 20 had ODA1 IDA defects, 41 had
IDA/CA/MTD defects, 12 had normal
ciliary ultrastructure, and nine had other
defects (oligocilia [n = 4] and isolated
CA defect [n = 5]). Of note, the genetic
mutations for the isolated ODA and
ODA/IDA groups included multiple PCD
genes; however, the genetic mutations for
the IDA/CA/MTD group (CCDC39 or
CCDC40) and for the normal ultrastructure
group (DNAH11 or RPGR) were each
limited to two genes (Table E1 in the online
supplement outlines diagnostic genetic
variants for each participant).
Baseline characteristics of the entire
cohort and categorized by ciliary
ultrastructure defect are shown in Table 2.
Participants with IDA/CA/MTD defects
were younger at age of initial diagnosis and
at enrollment, and had significantly lower
growth parameters (weight and body mass
index percentile) and percent predicted
FEV1 than participants with isolated ODA
defects. There were no differences in
baseline characteristics between the other
ciliary defect groups and the ODA defect
group.
Age-Specific Respiratory Microbiology
Respiratory cultures were obtained at 728 of
the 732 (99.4%) study visits with a median of
six cultures per participant (range, 2–6).
Most (70.3%) samples were expectorated
sputum; deep pharyngeal samples (29.7%)
were obtained from those unable to
expectorate, predominantly young children
less than or equal to 5 years of age
(Figure 2). Figure 2 is a cross-sectional plot
of the prevalence of bacteria isolated from
respiratory cultures by age category. Each
participant contributed data in each age
category in which culture results were
available.
The most common bacterial isolates
across all ages were H. influenzae and
S. aureus. P. aeruginosa and nontuberculous
mycobacteria were relatively less common.
During the study period, P. aeruginosa was
recovered from 40 participants, and mucoid
P. aeruginosa was isolated from seven
participants, including four who had
ODA defects (four DNAH5), two with
IDA/CA/MTD defects (one CCDC39,
one CCDC40), and one with an other
defect (RSPH4A). The youngest age for
P. aeruginosa recovery was 1.4 years
(deep oropharyngeal culture yielding
mucoid and nonmucoid P. aeruginosa in a
participant with IDA/CA/MTD- CCDC39).
P. aeruginosa infection was persistent
(recovered in sputum culture from at
least two consecutive annual visits) in
13 participants, including five participants
with ODA defects (four DNAH5, one
DNAI1), five with IDA/CA/MTD defects
(one CCDC39, three CCDC40, one with
no gene identified), two with normal
Excluded: did not meet
diagnostic criteria: 30
Excluded: did not have









Figure 1. Flowchart outlining the enrolled participants. PCD = primary ciliary dyskinesia; EM =
electron micrographs.
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axonemal ultrastructure (two DNAH11),
and one with a CA defect (RSPH4A). The
youngest age for persistent P. aeruginosa
was 4 years (positive culture at 4 and 5 yr
of age). Generalized estimating equations
analyses did not reveal a difference in
pathogen prevalence between defect
groups.
Association of Ciliary Ultrastructural
Defects with Lung Function and
Growth Parameters
Figure 3A compares percent predicted
FEV1 and weight-for-age and height-for-
age z-scores between ultrastructural defect
groups from linear mixed effects models.
Compared with those with isolated ODA
defects, participants with IDA/CA/MTD
defects had lower percent predicted FEV1
and growth measures. We also compared
percent predicted FEV1 and growth
parameters between PCD genetic groups
(Figure 3B). Compared with participants
with DNAH5 mutations, participants with
genetic mutations in CCDC39 or CCDC40
had lower percent predicted FEV1 and
weight and height z-scores. When preschool
spirometry was removed, the FEV1 values
for the IDA/CA/MTD group and for the
participants with CCDC39 and CCDC40
mutations remained significantly lower
than the ODA (P = 0.0002) and DNAH5
(P = 0.001) reference groups, respectively
(see the online supplement).
Longitudinal Changes in Lung
Function and Growth Status
The mean annual change in percent
predicted FEV1 was 20.57% per year (SE,
0.25; P = 0.03) for the cohort as a whole.
Figure 4 shows the variability in individual
patterns in percent predicted FEV1 change
over time for each defect group and the
estimated slopes from linear mixed effects
models. Slopes (mean [SE] predicted/yr)
were as follows: ODA (20.73 [0.38]; P =
0.06), ODA/IDA (20.48 [0.65]; P = 0.46),
IDA/CA/MTD (21.11 [0.48]; P = 0.02),
and normal EM (0.29 [0.88]; P = 0.75). The
rates of decline in the ODA, ODA/IDA,
and IDA/CA/MTD groups were not
significantly different from each other
(P = 0.56). When preschool spirometry was
removed for participants between the ages
of 3 and 5 years, the decline in FEV1 for the
IDA/CA/MTD group remained significant
(see the online supplement). Weight-for-
age and height-for-age z-scores did not
decline with age for any of the
ultrastructural defect groups (data not
shown).
Discussion
In this prospective, multicenter, longitudinal
North American study of children and
young adults with confirmed PCD, we
were able to detect different clinical
phenotypes based on ciliary ultrastructural
defect group and corresponding genotype.
Specifically, we found differences in lung
function and growth parameters, but not
pathogen prevalence. Participants with
IDA/CA/MTD defects had poorer lung
function at the time of enrollment and at all
ages compared with those with isolated
ODA defects. Furthermore, this was the only
group that had a significant decline in lung
function over time. Participants with
biallelic CCDC39 or CCDC40 pathogenic
variants also had lower FEV1 values and
weight and height z-scores compared with
those with genetic mutations in DNAH5. In
this cohort, growth parameters only seemed
to be affected in those with IDA/CA/MTD
defects, who had worse weight and height
Table 1. Ultrastructural and Genetic Findings
PCD-Causing Gene ODA ODA/IDA IDA/CA/MTD Normal EM Other: Oligocilia Other: CA Total
None identified 4 3 7 — — 1 15
DNAH5 36 — — — — — 36
DNAI1 7 — — — — — 7
DNAI2 5 — — — — — 5
CCDC114 2 — — — — — 2
ARMC4 1 — — — — — 1
LRRC6 — 3 — — — — 3
DYX1C1 — 3 — — — — 3
CCDC103 — 2 — — — — 2
HEATR2 — 2 — — — — 2
SPAG1 — 2 — — — — 2
DNAAF1 — 2 — — — — 2
DNAAF2 — 1 — — — — 1
DNAAF3 — 1 — — — — 1
PIH1D3 (X-linked) — 1 — — — — 1
CCDC40 — — 18 — — — 18
CCDC39 — — 16 — — — 16
DNAH11 — — — 11 — — 11
RPGR (X-linked) — — — 1 — — 1
CCNO — — — — 4 — 4
RSPH4A — — — — — 2 2
RSPH1 — — — — — 1 1
RSPH9 — — — — — 1 1
Total 55 20 41 12 4 5 137
Definition of abbreviations: CA = central apparatus; EM = electron micrographs; IDA = inner dynein arm; MTD =microtubular disorganization; ODA = outer
dynein arm; PCD = primary ciliary dyskinesia.
The 20 participants with diagnosis confirmed by genetics alone are classified into the appropriate ciliary defect group based on their PCD-causing gene
mutations.
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z-scores at every age compared with those
with ODA defects. The most common
respiratory organisms isolated were
H. influenzae and S. aureus. P. aeruginosa was
relatively uncommon in this young cohort,
but its prevalence rose during adolescence.
The prevalence of specific organisms did
not differ based on ultrastructural defect.
Participants with IDA/CA/MTD defects
were younger at age of initial diagnosis,
reinforcing the severity of disease in this
group.
Lung function change over time was
highly variable in our cohort, similar to
past reports (6, 16). In the entire cohort,
there was a significant decline in FEV1 over
time (mean, 20.57% predicted per year).
The fact that we were only able to detect
a significant rate of decline in the
IDA/CA/MTD group, despite these
participants having a younger age of
diagnosis and presumably earlier access to
specialized care, highlights the increased
risk for disease progression in this defect
group. Furthermore, the seven individuals
with the IDA/CA/MTD ultrastructural
defect without genetic confirmation also
had similar FEV1 values as the entire defect
group. A recently published single-center
study corroborated our findings, reporting
that children and adults with PCD who
had the MTD ultrastructural defect had
lower spirometric indices and worse lung
clearance index values when compared with
those with dynein arm defects or normal
ciliary ultrastructure (17). The findings
in our study should be interpreted with
caution, because our analyses had limited
statistical power because of small sample
sizes within each defect group. A past













Male, n (%) 67 (49) 27 (49) 12 (60) 21 (51) 3 (25) 4 (44)
Race, n (%)
White 112 (82) 48 (87) 13 (65) 32 (78) 10 (83) 9 (100)
Black 3 (2) — 1 (5) 2 (5) — —
Asian 16 (12) 4 (7) 6 (30) 4 (10) 2 (17) —
Native American 1 (,1) 1 (2) — — — —
Multiracial 3 (2) 2 (4) — 1 (2) — —
Not reported 2 (2) — — 2 (5) — —
Hispanic or Latino, n (%) 13 (9) 3 (5) 1 (5) 5 (12) 2 (17) 2 (22)
Age at initial diagnosis, yr, mean (SD) 3.9 (3.8) 4.8 (4.4) 3.2 (3.4) 2.5 (2.9)‡ 5.2 (2.8) 4.8 (3.1)
Age at enrollment, yr, mean (SD) 7.8 (4.6) 8.9 (4.3) 7.5 (5.6) 6.4 (4.4)‡ 9.0 (4.4) 7.1 (4.2)
Height percentile, mean (SD) 47.9 (30.5) 52.4 (31.4) 44.7 (32.8) 41.6 (25.8)‡ 56.5 (35.3) 38.4 (29.5)
Weight percentile, mean (SD) 52.6 (31.2) 60.8 (32.6) 49.9 (34.7) 40.4 (24.3)‡ 54.4 (31.6) 59.6 (29.5)
BMI percentile, mean (SD) 55.4 (31.1) 62.5 (30.7) 50.2 (34.8) 45.5 (26.6)‡ 52.1 (33.9) 65.3 (32.0)
FEV1 percent predicted (SD)
† 82.7 (19.1) 88.3 (17.4) 85.5 (21.4) 71.5 (18.4)‡ 86.1 (16.4) 81.0 (9.5)
Nasal NO, nl/min, mean (SD) 18.2 (20.1) 14.0 (9.1) 21.6 (24.2) 17.8 (14.0) 31.3 (48.4)‡ 27.4 (21.1)
Clinical features, n (%)
Laterality defect 71 (52) 32 (58) 10 (50) 21 (51) 8 (67) 0
Neonatal respiratory distress 111 (81) 43 (78) 18 (90) 36 (88) 9 (75) 5 (56)
Chronic cough 136 (99) 55 (100) 20 (100) 40 (98) 12 (100) 9 (100)
Chronic nasal congestion 134 (98) 54 (98) 19 (95) 40 (98) 12 (100) 9 (100)
Chronic otitis media 127 (93) 52 (95) 18 (90) 37 (90) 11 (92) 9 (100)
Definition of abbreviations: BMI = body mass index; CA = central apparatus; EM = electron micrographs; IDA = inner dynein arm; MTD =microtubular
disorganization; ODA = outer dynein arm.
*Includes oligocilia (n = 4) and central apparatus defect (n = 5).
†Baseline spirometry available from 92 participants; others were too young to perform spirometry at enrollment.





















< 5 6–8 9–11 12–14 15–17 18
52 68 77 60 44 22
106 54 25 14 12 5
Age (y)
Number of subjects (n)
Number of oropharyngeal cultures (n)
Number of expectorated cultures (n)35 96 137 116 84 44
Figure 2. Serial cross-sectional plot of the prevalence of bacteria isolated from respiratory cultures by
age category.
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single-center study demonstrated
stabilization of lung function in patients
who received a standardized approach to
care (16). However, our patients were
followed at multiple clinical sites with
different approaches to management.
Recent studies have shown that
children with PCD can have growth
deficiencies (18), but the association
between axonemal ultrastructure defect
or genotype and longitudinal growth
parameters has not previously been
reported. We found that growth was
generally normal in all groups, except
participants with IDA/CA/MTD
ultrastructural defects, who had lower
weight and height z-scores. Growth status
did not progressively decline with time in
any defect group. It is possible that the
impaired growth is related to increased
energy expenditure secondary to greater
work of breathing in this cohort, which has
been implicated in other suppurative airway
diseases (19, 20).
Another potential explanation for
poorer growth is greater upper airway
involvement leading to anosmia and
reduced appetite (21). A limitation of this
prospective study is that we did not collect
detailed data on upper airway disease.
Future studies evaluating the impact of
ultrastructural defects on the upper airway
would further elucidate potential mechanisms
for poor growth. The mechanism may
be unclear, but a more aggressive
approach to nutritional management may
be required in these patients. As reported
previously, a higher body mass index is
also associated with higher FEV1 and FVC
z-scores in PCD (22).
As previously reported (8–10),
the most common pathogens were
H. influenzae, S. aureus, and S. pneumoniae.
The higher prevalence of these organisms
in the younger participants may reflect the
predominantly upper airway source of their
respiratory cultures. As previously reported
in pediatric PCD cohorts, we saw a low
overall prevalence of P. aeruginosa. The
predominance of P. aeruginosa in adults
with PCD has been reported to be higher
and we saw a rise in P. aeruginosa during
adolescence. The observed decline in
prevalence of certain organisms with age
B
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DNAH11 MUTATIONS (N = 9)
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ODA/IDA MUTATIONS (N = 17)
Parameter estimate for FEV1
DNAH5 reference group (N = 35)
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CCDC39,CCDC40 MUTATIONS (N = 33)
DNAH11 MUTATIONS (N = 11)
ODA MUTATIONS (N = 15)
ODA/IDA MUTATIONS (N = 17)
Parameter estimate for weight
DNAH5 reference group (N = 36)
–1.5 –1.0 –0.5 0 0.5 1.0 1.5
CCDC39,CCDC40 MUTATIONS (N = 33)
DNAH11 MUTATIONS (N = 11)
ODA MUTATIONS (N = 15)
ODA/IDA MUTATIONS (N = 17)
Parameter estimate for height
DNAH5 reference group (N = 36)
A
–25 –20 –15 –10 –5 0 5 10 15
ODA/IDA (n = 20)
IDA/CA/MTD (N = 37)
Normal EM (N = 10)
Parameter estimate for FEV1
ODA reference group (N = 52)
–1.5 –1.0 –0.5 0 0.5 1.0 1.5
ODA/IDA (N = 20)
IDA/CA/MTD (N = 40)
Normal EM (N = 12)
Parameter estimate for weight
ODA reference group (N = 55)
–1.5 –1.0 –0.5 0 0.5 1.0 1.5
ODA/IDA (N = 20)
IDA/CA/MTD (N = 40)
Normal EM (N = 12)
Parameter estimate for height
ODA reference group (N = 55)
Figure 3. (A) Forest plots of association of percent predicted FEV1 and weight and height z-scores with ciliary ultrastructural defects: ODA (reference
group, n = 55), ODA/IDA (n = 20), IDA/CA/MTD (n = 40), and normal EM (n = 12). Linear mixed effects models including data from all study visits were used
to estimate the overall association between clinical feature and defect group. (B) Forest plots of association of percent predicted FEV1 and weight and
height z-scores with primary ciliary dyskinesia mutations. DNAH5 (reference group, n = 36), CCDC39 and CCDC40 (n = 33), DNAH11 (n = 11), other ODA
(n = 15), and ODA/IDA (n = 17). Linear mixed effects models including data from all study visits were used to estimate the overall association between
clinical feature and genetic defect group. CA = central apparatus; EM = electron micrographs; IDA = inner dynein arm; MTD =microtubular disorganization;
ODA = outer dynein arm.
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may also reflect overgrowth of cultures
by P. aeruginosa in older patients or
differences in yield from oropharyngeal
cultures versus expectorated sputum.
Historically, the progression of PCD
lung disease has been thought to be
milder than that of cystic fibrosis (CF),
although some patients with PCD have
lung disease severe enough to require lung
transplant in adulthood (23). Few studies
have directly compared the two
conditions (24–26). In our cohort, mean
FEV1 was 83–93% predicted at age 5
depending on the defect group,
potentially slightly lower than that of
contemporary young patients with CF
(27). However, great caution must be
taken in relating observed lung function
in PCD to CF cohorts. Comparisons
require careful matching and the same
analytic methods in both disease cohorts.
Compared with pediatric CF cohorts (27),
the prevalence of airway infection with P.
aeruginosa is lower, although children
with PCD seem to be more symptomatic
at a younger age, with daily productive
cough and persistent nasal congestion
that begins in early infancy (5). The
relative preservation of cough clearance in
PCD may delay or prevent chronic
colonization with P. aeruginosa during
childhood. Alternatively, there are likely
differences in airway surface liquid
composition, mucus rheology, or innate
airway defenses between CF and PCD that
could explain the apparent difference in
predilection for P. aeruginosa infection.
Understanding the underlying
mechanisms for more severe airway disease
in individuals with IDA/CA/MTD defects,
often associated with mutations in CCDC39
or CCDC40, is imperative for developing
interventions. CCDC39 and CCDC40
function as cilia “rulers,” directing the
spacing and arrangement of the IDAs and
radial spokes (28). CCDC39 and CCDC40
are integral components within the nexin-
dynein regulatory complex, which is central
for controlling the rhythmic motion of cilia
(29–31). Genetic mutations in either
CCDC39 or CCDC40 are associated with an
abnormal ciliary beat pattern, in which
most (up to 75%) cilia are static and the rest
move with a rigid and ineffective beat (32,
33). For ODA defects, a smaller proportion
of cilia are static and those that move have a
stiff beat pattern, but not as rigid as the
ciliary beat for IDA/CA/MTD defects
(32–34). It seems unlikely that these
differences in ciliary motion could account
for the increased severity of lung disease
in patients with IDA/CA/MTD defects.
Conceivably, CCDC39 and CCDC40 may
have a role in other nonepithelial cells
that affect lung health. Early studies showed
that neutrophils extracted from some
individuals with PCD may have defective
motility causing impaired chemotaxis and
bacterial killing (35, 36). Because these
studies were performed before the advent of
genetic testing, it is unclear whether the
neutrophil phenotype is related to specific
PCD genotypes. A recent study demonstrated
that neutrophils from patients with PCD with
different ultrastructural and genetic defects
had reduced chemotaxis compared with
healthy control subjects (37), but only one
of these individuals had a genetic defect in
CCDC39 or CCDC40.
The strengths of this study are its
prospective, longitudinal, multicenter study
design and the use of rigorous, standardized
diagnostic criteria, based on hallmark
ultrastructure defects and/or genetic
testing, which has allowed us to uncover
ultrastructural and genotype-phenotype
relationships in PCD. Nevertheless, PCD is
still a largely underrecognized, rare disease.
The relatively small sample size for each
defect group limited our ability to detect
differences between groups in clinical
parameters, particularly FEV1 decline.
Moreover, environmental factors and
treatment strategies may have varied across
sites, thus potentially impacting outcomes,
especially if particular ultrastructural
and/or genetic defects were overrepresented
or underrepresented at a particular site. All
participants in this study received clinical
care at local institutions and were referred
to the research sites for participation in this
study. Because of relatively small numbers
at each site, we were unable to assess this
potential bias. A larger, international
approach to studying rare lung diseases,
such as PCD, is critical for future
investigations to better identify predictors
of bronchiectasis and lung function decline.
Earlier identification of patients at higher
risk for severe disease could alter early
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Figure 4. Estimated mean annual change in percent predicted FEV1 (ppFEV1) for each ciliary
ultrastructural defect. (A–D) Change in lung function with age for each individual in each defect group,
with the estimated slope for that defect group superimposed. (A) ODA, ppFEV1 = 95.542 0.733 age
(yr). (B) ODA1 IDA, ppFEV1 = 88.222 0.483 age (yr). (C) IDA/CA/MTD, ppFEV1 = 85.542 1.13
age (yr). (D) Normal EM, ppFEV1 = 85.771 0.293 age (yr). Estimated slopes are from linear mixed
effects models including ultrastructure defect group, age in years, and the interaction between
them as fixed effects. Individuals with the bold lines are those who were diagnosed based on an
ultrastructural defect without a corresponding genetic mutation. For definition of abbreviations,
see Figure 3.
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outcomes. In addition, an improved
understanding of the impact of nutrition on
respiratory disease severity among patients
with PCD could aid management. Next
steps in our cohort include refining the
genotype and ultrastructural relationships
to lung function, structure and growth
parameters, and evaluating predictors of
rate of lung function decline, such as
nutritional status. n
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